Evan Barry

1.8k total citations
17 papers, 1.4k citations indexed

About

Evan Barry is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Evan Barry has authored 17 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Hepatology. Recurrent topics in Evan Barry's work include Cancer Mechanisms and Therapy (5 papers), Liver physiology and pathology (5 papers) and Hippo pathway signaling and YAP/TAZ (4 papers). Evan Barry is often cited by papers focused on Cancer Mechanisms and Therapy (5 papers), Liver physiology and pathology (5 papers) and Hippo pathway signaling and YAP/TAZ (4 papers). Evan Barry collaborates with scholars based in United States, United Kingdom and Netherlands. Evan Barry's co-authors include Fernando D. Camargo, Teppei Morikawa, Kriti Shrestha, Calvin J. Kuo, Charles S. Fuchs, Ron Smits, Kelley S. Yan, Shuji Ogino, Scott T. Magness and Rosemarie de la Rosa and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Cancer Research.

In The Last Decade

Evan Barry

17 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Evan Barry United States 11 891 841 240 106 90 17 1.4k
Fan Xia China 7 754 0.8× 1.0k 1.2× 151 0.6× 36 0.3× 87 1.0× 9 1.3k
Gonzalo Fernández‐Miranda Spain 14 739 0.8× 292 0.3× 207 0.9× 39 0.4× 218 2.4× 19 968
Mark R. Silvis United States 13 662 0.7× 639 0.8× 134 0.6× 221 2.1× 89 1.0× 19 1.1k
Garrett T. Graham United States 17 774 0.9× 412 0.5× 355 1.5× 191 1.8× 248 2.8× 31 1.3k
Sue Penrhyn-Lowe United Kingdom 5 520 0.6× 430 0.5× 281 1.2× 23 0.2× 111 1.2× 8 892
Takashi Tatsumoto Japan 13 611 0.7× 405 0.5× 246 1.0× 73 0.7× 45 0.5× 17 896
Siew Wee Chan Singapore 20 1.6k 1.8× 2.1k 2.5× 315 1.3× 69 0.7× 122 1.4× 24 2.7k
Emily E. Bosco United States 12 654 0.7× 229 0.3× 463 1.9× 157 1.5× 207 2.3× 21 1.1k
Juan M. Schvartzman United States 8 797 0.9× 528 0.6× 342 1.4× 58 0.5× 273 3.0× 12 1.1k

Countries citing papers authored by Evan Barry

Since Specialization
Citations

This map shows the geographic impact of Evan Barry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evan Barry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evan Barry more than expected).

Fields of papers citing papers by Evan Barry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evan Barry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evan Barry. The network helps show where Evan Barry may publish in the future.

Co-authorship network of co-authors of Evan Barry

This figure shows the co-authorship network connecting the top 25 collaborators of Evan Barry. A scholar is included among the top collaborators of Evan Barry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evan Barry. Evan Barry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Barry, Evan, et al.. (2021). Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine. Cells. 10(10). 2715–2715. 51 indexed citations
2.
Reddy, Venkatesh Pilla, Rana Anjum, Michael Grondine, et al.. (2020). The Pharmacokinetic–Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST. Clinical Cancer Research. 26(14). 3751–3759. 9 indexed citations
3.
Jones, Rhys D.O., Alexandra Borodovsky, Maryann San Martin, et al.. (2020). A pharmacokinetic–pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti‐tumour activity. British Journal of Pharmacology. 178(3). 600–613. 6 indexed citations
4.
5.
Myant, Kevin, Patrizia Cammareri, Michael C. Hodder, et al.. (2016). HUWE 1 is a critical colonic tumour suppressor gene that prevents MYC signalling, DNA damage accumulation and tumour initiation. EMBO Molecular Medicine. 9(2). 181–197. 56 indexed citations
6.
Ladd, Brendon, Anne Marie Mazzola, Teeru Bihani, et al.. (2016). Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations. Oncotarget. 7(34). 54120–54136. 22 indexed citations
7.
Barry, Evan, Elizabeth M. Maloney, Ryan E. Henry, et al.. (2016). Abstract 1150: Targeting MET Exon 14 mutations with the selective small molecule inhibitor Savolitinib. Cancer Research. 76(14_Supplement). 1150–1150. 1 indexed citations
8.
Henry, Ryan E., Evan Barry, Lillian Castriotta, et al.. (2016). Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation. Oncotarget. 7(36). 57651–57670. 27 indexed citations
9.
Schuller, Alwin G., Evan Barry, Rhys D.O. Jones, et al.. (2015). The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models. Clinical Cancer Research. 21(12). 2811–2819. 57 indexed citations
10.
D’Cruz, Celina M., Evan Barry, Ryan E. Henry, et al.. (2015). Abstract 761: Changing the paradigm for treating drug resistance in NSCLC: Novel combinations of AZD6094, a selective MET inhibitor, and an irreversible, selective (EGFRm/T790M) EGFRTKI, AZD9291. Cancer Research. 75(15_Supplement). 761–761. 2 indexed citations
11.
D’Cruz, Celina M., Melanie M. Frigault, Ammar Adam, et al.. (2014). Abstract 3114: Targeting MET in preclinical models to support the clinical development of Volitinib in NSCLC. Cancer Research. 74(19_Supplement). 3114–3114. 6 indexed citations
12.
Barry, Evan & Fernando D. Camargo. (2013). The Hippo superhighway: signaling crossroads converging on the Hippo/Yap pathway in stem cells and development. Current Opinion in Cell Biology. 25(2). 247–253. 171 indexed citations
13.
Barry, Evan, Teppei Morikawa, Kriti Shrestha, et al.. (2012). Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature. 493(7430). 106–110. 433 indexed citations
14.
Zhou, Dawang, Yongyou Zhang, Hongtan Wu, et al.. (2011). Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proceedings of the National Academy of Sciences. 108(49). E1312–20. 377 indexed citations
15.
Barry, Evan, Gareth N. Corry, & Theodore P. Rasmussen. (2010). Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development. Expert Opinion on Therapeutic Targets. 14(4). 405–418. 26 indexed citations
16.
Corry, Gareth N., Borko Tanasijevic, Evan Barry, Winfried Krueger, & Theodore P. Rasmussen. (2009). Epigenetic regulatory mechanisms during preimplantation development. Birth Defects Research Part C Embryo Today Reviews. 87(4). 297–313. 58 indexed citations
17.
Barry, Evan, et al.. (2009). ES Cell Cycle Progression and Differentiation Require the Action of the Histone Methyltransferase Dot1L. Stem Cells. 27(7). 1538–1547. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fan Xia Breakdown of academic impact, for papers by Gonzalo Fernández‐Miranda Breakdown of academic impact, for papers by Mark R. Silvis Breakdown of academic impact, for papers by Garrett T. Graham Breakdown of academic impact, for papers by Sue Penrhyn-Lowe Breakdown of academic impact, for papers by Takashi Tatsumoto Breakdown of academic impact, for papers by Siew Wee Chan Breakdown of academic impact, for papers by Emily E. Bosco Breakdown of academic impact, for papers by Juan M. Schvartzman
Rankless by CCL
2026